Serving hundreds of leading biopharmaceutical companies globally:

Generated: August 24, 2019

DrugPatentWatch Database Preview

Patent: 9,321,812

Try a free trial

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,321,812

Title:	Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptide
Abstract:	Embodiments of the present invention provide for novel therapies, pharmaceutical compositions and methods for insulin independence utilizing a new optimized hamster Reg3 gamma peptide, which is new to the art and has not previously been considered for development in the 30 year history since its discovery. Methods, pharmaceutical compositions and therapies novel to the prior art are utilized in this invention to render patients with recent onset and existing type 1 diabetes insulin independent by an optimized hamster Reg3 gamma peptide and an immune tolerance agent for type 1 patients to become insulin independent and used alone without an immune tolerance agent for type 2 diabetes. While not wishing to be bound by theory, optimized Reg3 gamma peptides increases beta cell generation by its demonstrated properties shown within of transforming ductal pancreatic cells into new islets.
Inventor(s):	Levetan; Claresa (Bryn Mawr, PA)
Assignee:	Perle Bioscience (Charleston, SC)
Application Number:	14/453,414
Patent Claims:	see list of patent claims

Details for Patent 9,321,812

Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Biogen	ZINBRYTA	daclizumab	INJECTABLE;INJECTION	761029	001	2016-05-27	➤ Sign Up	Perle Bioscience (Charleston, SC)	2036-05-13	RX		search
Genzyme	LEMTRADA	alemtuzumab	INJECTABLE;INJECTION	103948	003	2001-05-07	➤ Sign Up	Perle Bioscience (Charleston, SC)	2036-05-13	RX	Orphan	search
Genzyme	CAMPATH	alemtuzumab	VIAL; INTRAVENOUS	103948	002	2001-05-07	➤ Sign Up	Perle Bioscience (Charleston, SC)	2036-05-13	RX	Orphan	search
Genzyme	CAMPATH	alemtuzumab	VIAL; INTRAVENOUS	103948	001	2001-05-07	➤ Sign Up	Perle Bioscience (Charleston, SC)	2036-05-13	RX	Orphan	search
Genentech	RITUXAN	rituximab	VIAL	103705	001	1997-11-26	➤ Sign Up	Perle Bioscience (Charleston, SC)	2036-05-13	RX		search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

International Patent Family for US Patent 9,321,812

Subscribe to access the full database, or try a Free Trial
Country	Patent Number	Publication Date
World Intellectual Property Organization (WIPO)	2015148831	Oct 01, 2015
United States of America	10010577	Jul 03, 2018
United States of America	10010578	Jul 03, 2018
United States of America	10010579	Jul 03, 2018
United States of America	10010580	Jul 03, 2018
>Country	>Patent Number	>Publication Date

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.